title: [Drug treatment in type 2 diabetes (part 2)].
abstract: Insulin secretagogues and insulin sensitizers can be combined with one another as well as with other treatments (described below). Alpha-glucosidase inhibitors delay intestinal absorption of carbohydrates and reduce postprandial glycemia. Orlistat and sibutramine improve insulin sensitivity by helping patients lose weight. Orlistat inhibits hydrolysis of dietary triglycerides. Sibutramine, a noradrenaline and serotonin reuptake inhibitor, reinforces feelings of satiety and increases energy expenditure. After approximately 10 years, insulin therapy is usually required together with oral antidiabetic agents (except glitazones) or alone if HbA(1c) (glycosylated hemoglobin) is>6.5%. New guidelines for management of type 2 diabetes were published in 2006.
authors.affiliation: Service de Médecine Interne B, AP-HP, Hôpital Lariboisière, Paris.
authors.forename: Amélie
authors.initials: A
authors.lastname: Tielmans
authors.forename: Marie
authors.initials: M
authors.lastname: Virally
authors.forename: Muriel
authors.initials: M
authors.lastname: Coupaye
authors.forename: Marie
authors.initials: M
authors.lastname: Laloi-Michelin
authors.forename: Taly
authors.initials: T
authors.lastname: Méas
authors.forename: Pierre-Jean
authors.initials: PJ
authors.lastname: Guillausseau
mesh_terms: D019440:Anti-Obesity Agents / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007328:Insulin / Q000627:therapeutic use
chemical_list: D019440:Anti-Obesity Agents; D065089:Glycoside Hydrolase Inhibitors; D007328:Insulin